Evidence map›Paper›PMID 36425431›Full record

ReviewHeliyon2022

Mechanotransduction of mesenchymal stem cells (MSCs) during cardiomyocytes differentiation.

Narmadaa Raman, Siti A M Imran, Khairul Bariah Ahmad Amin Noordin, Wan Safwani Wan Kamarul Zaman, Fazlina Nordin

Abstract readReview
In one paragraph

Review in Heliyon, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Narmadaa RamanCentre for Tissue Engineering and Regenerative Medicine (CTERM), Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latiff, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Malaysia.
Siti A M ImranCentre for Tissue Engineering and Regenerative Medicine (CTERM), Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latiff, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Malaysia.
Khairul Bariah Ahmad Amin NoordinSchool of Dental Sciences, Universiti Sains Malaysia, Kampus Kesihatan Kubang Kerian, 16150 Kubang Kerian, Kelantan, Malaysia.
Wan Safwani Wan Kamarul ZamanDepartment of Biomedical Engineering, Faculty of Engineering, Universiti Malaya, 50603 Kuala Lumpur, Malaysia.
Fazlina NordinCentre for Tissue Engineering and Regenerative Medicine (CTERM), Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latiff, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiac muscle cells have an innate capacity to perceive and react to mechanical strain via a mechanism known as mechanotransduction, whereby the cardiac muscle cells are intrinsically capable of sensing and responding to mechanical strain. This process occurs in the heart when mechanical inputs are converted to biochemical processes that result in myocardial structure and function changes. Mechanotransduction and its downstream effects work as compensatory mechanisms during early load adaptation. However, prolonged, and aberrant loading may cause maladaptive remodeling, resulting in altered physiological function, pathological cardiac hypertrophy, and heart failure. The rapid advancement of stem cell research has raised the hopes of both patients and clinicians. Mesenchymal progenitors have become one of the most intriguing possibilities for treating illnesses ranging from cartilage abnormalities to heart issues. Their immunomodulatory properties have also allowed for allogenic usage, besides expanding their potential for cardiomyocyte applications. In the present review, we highlighted mesenchymal stem cells (MSCs) in cardiovascular mechanotransduction, differentiation of cardiomyocytes and the use of MSCs in cardiovascular disease and tissue engineering.

Indexed as

CardiomyocytesCardiovascular mechanotransductionDifferentiation of mesenchymal stem cells (MSCs)Mechanical forcesMesenchymal stem cells (MSCs) therapyTissue engineering

Identifiers

PMID36425431
PMCPMC9678689

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.